Immunovant Inc (IMVT) Stock Analysis

Immunovant Inc (IMVT) is a publicly traded company in the HEALTHCARE sector. It trades at $30.92, carries a market capitalization of $6.75B. This page summarizes the public market data, fundamentals, and frequently asked questions for IMVT, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $30.92
• Market Cap: $6.75B
• EPS: $-2.77
• 52-Week High: $36.28
• 52-Week Low: $14.32

Market Sentiment

Immunovant Inc currently has a Bullish sentiment score of 0.22.

About Immunovant Inc

Immunovant, Inc. is a clinical-stage biopharmaceutical company headquartered in New York, dedicated to developing innovative monoclonal antibody therapies for autoimmune disorders. Its lead candidate, batoclimab, specifically targets critical pathways implicated in these diseases and is currently being evaluated in multiple clinical trials to establish its efficacy and safety profile. With a promising pipeline and a strategic focus on addressing significant unmet medical needs within immunolo...

GNG Research Analysis

GNG Research scores Immunovant Inc (IMVT) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for IMVT.

Frequently Asked Questions

Does IMVT pay dividends?

Immunovant Inc (IMVT) does not currently pay a regular dividend.

What is IMVT's market cap?

Immunovant Inc (IMVT) has a market capitalization of $6.75B with a current stock price of $30.92.